RED
BANK, N.J., Feb. 8, 2023
/PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a
biopharmaceutical company dedicated to intercepting and preventing
immune-mediated diseases, today announced that management will
participate in a fireside chat presentation at the SVB Securities
Global Biopharma Conference on Wednesday,
February 15th, 2023 at 11:20am EST.
The presentation will be webcast live and can be accessed by
visiting the Events and Webcasts section of the Company's website:
http://investors.proventionbio.com/events. The webcast will be
archived on the Company's website for 30 days following the
presentation.
About Provention Bio, Inc.:
Provention Bio, Inc. (Nasdaq: PRVB) is a commercial-stage
biopharmaceutical company focused on advancing the development and
commercialization of investigational therapies that may intercept
and prevent debilitating and life-threatening immune-mediated
diseases. The Company's pipeline includes clinical-stage product
candidates that have demonstrated in pre-clinical or clinical
studies proof-of-mechanism and/or proof-of-concept in autoimmune
diseases, including T1D, celiac disease and lupus. Visit
www.ProventionBio.com for more information and follow us on
Twitter: @ProventionBio.
Internet Posting of Information:
Provention Bio, Inc. uses its
website, www.proventionbio.com, as a means of disclosing
material nonpublic information and for complying with its
disclosure obligations under Regulation F.D. Such disclosures will
be included on the Company's website in the "News" section.
Accordingly, investors should monitor this portion of the Company's
website, in addition to following its press
releases, SEC filings and public conference calls and
webcasts.
Investor Contact:
Kristen
Kelleher, Senior Manager, Investor Relations
investorrelations@proventionbio.com
Media Contact:
Kaelan
Hollon, VP, Corporate Communications
khollon@proventionbio.com
202-421-4921
View original content to download
multimedia:https://www.prnewswire.com/news-releases/provention-bio-to-present-at-the-svb-securities-global-biopharma-conference-301740966.html
SOURCE Provention Bio, Inc.